Eterna Therapeutics Inc. (NASDAQ:ERNA – Get Free Report) was the target of a significant growth in short interest in June. As of June 15th, there was short interest totalling 55,000 shares, a growth of 15.3% from the May 31st total of 47,700 shares. Based on an average daily volume of 7,100 shares, the short-interest ratio is presently 7.7 days. Currently, 2.0% of the shares of the stock are short sold.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Eterna Therapeutics by 30.6% in the third quarter. Vanguard Group Inc. now owns 24,898 shares of the company’s stock valued at $54,000 after acquiring an additional 5,830 shares in the last quarter. Sippican Capital Advisors raised its stake in shares of Eterna Therapeutics by 92.3% in the fourth quarter. Sippican Capital Advisors now owns 54,050 shares of the company’s stock valued at $97,000 after acquiring an additional 25,950 shares in the last quarter. Lake Street Advisors Group LLC acquired a new stake in shares of Eterna Therapeutics in the fourth quarter valued at $933,000. Finally, Avidian Wealth Solutions LLC acquired a new stake in shares of Eterna Therapeutics in the first quarter valued at $36,000. 70.55% of the stock is currently owned by institutional investors and hedge funds.
Eterna Therapeutics Price Performance
Shares of Eterna Therapeutics stock opened at $1.83 on Monday. Eterna Therapeutics has a fifty-two week low of $0.84 and a fifty-two week high of $2.99. The company has a current ratio of 0.79, a quick ratio of 0.79 and a debt-to-equity ratio of 3.03. The stock has a 50 day moving average of $1.94 and a 200 day moving average of $1.91.
About Eterna Therapeutics
Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.
See Also
- Five stocks we like better than Eterna Therapeutics
- How to buy stock: A step-by-step guide for beginners
- Chewy Stock Surges on Roaring Kitty’s Disclosure of Major Stake
- Transportation Stocks Investing
- How to Invest in Gold: A Complete Guide
- What Investors Need to Know to Beat the Market
- 3 Stocks Wall Street Could Be Watching on Fannie Mae’s Rally
Receive News & Ratings for Eterna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eterna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.